Amgen Inc.
TREATMENT OF OVARIAN CANCER IN PATIENTS WITH ASCITES USING A SPECIFIC BINDING AGENT OF HUMAN ANGIOPOIETIN-2 IN COMBINATION WITH A TAXANE
Last updated:
Abstract:
Methods and compositions for treating ovarian cancer in a human patient with ascites by administering a therapeutically effective amount of an Ang2 inhibitor in combination with a taxane.
Status:
Application
Type:
Utility
Filling date:
3 Nov 2020
Issue date:
4 Mar 2021